PuSH - Publikationsserver des Helmholtz Zentrums München

Belloni, B.* ; Andres, C.* ; Ollert, M.* ; Ring, J. ; Mempel, M.

Novel immunological approaches in the treatment of atopic eczema.

Curr. Opin. Allergy Clin. Immunol. 8, 423-427 (2008)
DOI
Open Access Gold möglich sobald Verlagsversion bei der ZB eingereicht worden ist.
Atopic eczema is a common inflammatory skin disease showing chronically relapsing eczema and high association with elevated serum IgE levels. A subgroup of atopic eczema patients requires systemic immunomodulatory treatment for long time periods. However, beyond cyclosporine A and azathioprine, only limited consent exists on systemic treatment options. RECENT FINDINGS: Timely published systemic treatment modalities include studies on efalizumab (anti-CD11a antibody), infliximab, adalimumab, and etanercept (anti-TNF-alpha treatment), omalizumab (an anti-IgE antibody), rituximab (an anti-CD20 antibody), specific immunotherapy, leflunomide, and leukotriene receptor antagonists with varying clinical results and with particular safety profiles. SUMMARY: Although there is not yet a treatment modality reaching clinical efficacy of cyclosporine A as gold standard of systemic therapy, limitation in its application duration as in its side effect profile as well as the search for alternatives has set a focus on the new alternatives of which especially B-cell-directed therapies might be promising candidates.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter atopic eczema; efalizumab; leukotriene receptor antagonists; omalizumab; rituximab; sublingual immunotherapy; tumor necrosis factor-alpha antagonists
ISSN (print) / ISBN 1528-4050
e-ISSN 1473-6322
Zeitschrift Current Opinion in Allergy and Clinical Immunology
Quellenangaben Band: 8, Heft: 5, Seiten: 423-427 Artikelnummer: , Supplement: ,
Verlag Lippincott Williams & Wilkins
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Lung Health and Immunity (LHI)
Institute of Epidemiology (EPI)